Hepatitis Vaccine

Production, Storage and Handling of Vaccines

That investigation forecasts the overall hepatitis therapies market will multiply in revenues from 2014 to 2025. That pharmaceutical segment is evolving. Newly approved medications are achieving commercial success and some products blockbuster status. Visiongain believes the strength of the hepatitis drugs market is its oral antiviral treatments enabling shorter treatment regimens and higher cure rates, reportedly with fewer side effects than the standard care – peginterferon and ribavirin. Sales expansion of the market will be stimulated by the approval and continued development of interferon- and ribavirin-free regimens as well as increased screening. The potential for the hepatitis therapies market is vast and budgetary cuts and regulatory hurdles will not derail its progress.

 “In 2014, the greatest interest in the hepatitis C market is the development of protease and polymerase antivirals. Several companies have molecules in phase II and III trials, with at least five expected to gain approval within the first half of our forecast period. The overall world hepatitis C drug market was worth $4bn in 2013, and we expect it to multiply in annual revenue by 2025. There exists promising R&D for those medicines, with high sales potential from this decade onwards. That market is rapidly developing and will contribute high revenues to the pharmaceuticals industry from 2015 to 2025.”

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• International HBV Meeting, Germany
• HepDart 2015, Hawaii; The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada